DE69625361D1 - Alkyl amin derivate von substituierte chinoscalin 2,3-dione als glutamat rezeptor antagonisten - Google Patents

Alkyl amin derivate von substituierte chinoscalin 2,3-dione als glutamat rezeptor antagonisten

Info

Publication number
DE69625361D1
DE69625361D1 DE69625361T DE69625361T DE69625361D1 DE 69625361 D1 DE69625361 D1 DE 69625361D1 DE 69625361 T DE69625361 T DE 69625361T DE 69625361 T DE69625361 T DE 69625361T DE 69625361 D1 DE69625361 D1 DE 69625361D1
Authority
DE
Germany
Prior art keywords
substituted
chinoscaline
dione
receptor antagonist
alkyl amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69625361T
Other languages
English (en)
Other versions
DE69625361T2 (de
Inventor
Edward Kornberg
Sham Nikam
Francis Rafferty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE69625361D1 publication Critical patent/DE69625361D1/de
Application granted granted Critical
Publication of DE69625361T2 publication Critical patent/DE69625361T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69625361T 1995-06-07 1996-05-13 Alkyl amin derivate von substituierte chinoscalin 2,3-dione als glutamat rezeptor antagonisten Expired - Fee Related DE69625361T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/474,876 US5654303A (en) 1995-06-07 1995-06-07 Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
PCT/US1996/006818 WO1996040651A1 (en) 1995-06-07 1996-05-13 Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Publications (2)

Publication Number Publication Date
DE69625361D1 true DE69625361D1 (de) 2003-01-23
DE69625361T2 DE69625361T2 (de) 2003-04-17

Family

ID=23885301

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625361T Expired - Fee Related DE69625361T2 (de) 1995-06-07 1996-05-13 Alkyl amin derivate von substituierte chinoscalin 2,3-dione als glutamat rezeptor antagonisten

Country Status (24)

Country Link
US (1) US5654303A (de)
EP (1) EP0837854B1 (de)
JP (1) JPH11506725A (de)
KR (1) KR19990022481A (de)
AT (1) ATE229512T1 (de)
AU (1) AU716156B2 (de)
BG (1) BG63462B1 (de)
CA (1) CA2219755A1 (de)
CZ (1) CZ290899B6 (de)
DE (1) DE69625361T2 (de)
DK (1) DK0837854T3 (de)
EA (1) EA000762B1 (de)
EE (1) EE03683B1 (de)
ES (1) ES2187650T3 (de)
HU (2) HUP9900883A3 (de)
MX (1) MX9708431A (de)
NO (1) NO309088B1 (de)
NZ (1) NZ308318A (de)
PL (1) PL186764B1 (de)
PT (1) PT837854E (de)
SK (1) SK283181B6 (de)
UA (1) UA48183C2 (de)
WO (1) WO1996040651A1 (de)
ZA (1) ZA964760B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT784054E (pt) * 1994-09-27 2002-05-31 Yamanouchi Pharma Co Ltd Derivados de tetraidroquinoxalinadiona 1,2,3,4 e sua utilizacao como antagonistas do receptor glutamato
WO1997046539A1 (en) * 1996-06-05 1997-12-11 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
EP2338492A1 (de) 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
CN110642798B (zh) * 2019-11-10 2020-07-24 湖南科技学院 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) * 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
JPH05117276A (ja) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd 新規な3環性キノキサリンジオン誘導体
JPH06228112A (ja) * 1993-02-05 1994-08-16 Yamanouchi Pharmaceut Co Ltd (1h,4h)キノキサリン誘導体
TW260660B (de) * 1993-04-22 1995-10-21 Sumitomo Pharma
CA2161783C (en) * 1993-05-13 2006-08-15 Frank Watjen Ampa antagonists and a method of treatment therewith
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Also Published As

Publication number Publication date
HUP9900883A3 (en) 2001-02-28
NO309088B1 (no) 2000-12-11
PT837854E (pt) 2003-03-31
EE03683B1 (et) 2002-04-15
CZ387297A3 (cs) 1998-05-13
NO975703L (no) 1997-12-05
EE9700338A (et) 1998-06-15
US5654303A (en) 1997-08-05
KR19990022481A (ko) 1999-03-25
WO1996040651A1 (en) 1996-12-19
HUP9802568A2 (hu) 1999-03-29
AU5792096A (en) 1996-12-30
BG63462B1 (bg) 2002-02-28
BG102079A (en) 1998-11-30
HUP9802568A3 (en) 2000-01-28
EA000762B1 (ru) 2000-04-24
JPH11506725A (ja) 1999-06-15
HUP9900883A2 (hu) 1999-09-28
MX9708431A (es) 1998-02-28
AU716156B2 (en) 2000-02-17
DK0837854T3 (da) 2003-03-31
EP0837854B1 (de) 2002-12-11
SK169097A3 (en) 1998-07-08
NO975703D0 (no) 1997-12-05
SK283181B6 (sk) 2003-03-04
ZA964760B (en) 1997-01-08
PL186764B1 (pl) 2004-02-27
EP0837854A1 (de) 1998-04-29
DE69625361T2 (de) 2003-04-17
ES2187650T3 (es) 2003-06-16
CA2219755A1 (en) 1996-12-19
CZ290899B6 (cs) 2002-11-13
PL323824A1 (en) 1998-04-27
EA199800008A1 (ru) 1998-06-25
NZ308318A (en) 2001-04-27
ATE229512T1 (de) 2002-12-15
UA48183C2 (uk) 2002-08-15

Similar Documents

Publication Publication Date Title
ATE223388T1 (de) Amino-säure-derivate von substituierten chinoscalin 2,3-dion derivate als glutamat rezeptor antagonisten
ATE368650T1 (de) Kondensierte azepinderivate und ihre verwendung als als antidiuretisches mittel
IL178839A0 (en) Heterocyclic condensed compounds useful as antidiuretic agents
DE69625361T2 (de) Alkyl amin derivate von substituierte chinoscalin 2,3-dione als glutamat rezeptor antagonisten
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
DE69623463D1 (de) Zyklische amin derivate von substituierten chinoxalin 2.3-dione als glutamat-rezeptor-antagonisten
BG105710A (en) 5ht1 antagonists for antidepressant therapy
ATE263143T1 (de) Cyclopentylalkylnitrile und die verwendung von cyclopentylalkyl-derivaten als duftstoffe
FI960051A (fi) Difluoristatonianalogeja
CO5310533A1 (es) Derivados de amida de 2,3-dionas de quinoxalina como antago- nistas de receptor de glutamato
ID28292A (id) Senyawa 2,3,3a,4,9,9a-heksahidro-8-hidroksi-1h-benz (f) indol baru metoda untuk memproduksinya dan penggunaannya sebagai obat-obatan

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee